Prosperitas Financial LLC Sells 93 Shares of Eli Lilly and Company (NYSE:LLY)

Prosperitas Financial LLC trimmed its position in Eli Lilly and Company (NYSE:LLY) by 3.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,633 shares of the company’s stock after selling 93 shares during the quarter. Eli Lilly and Company accounts for 1.1% of Prosperitas Financial LLC’s holdings, making the stock its 29th biggest holding. Prosperitas Financial LLC’s holdings in Eli Lilly and Company were worth $1,535,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. SVB Wealth LLC grew its holdings in Eli Lilly and Company by 2.3% in the 4th quarter. SVB Wealth LLC now owns 16,304 shares of the company’s stock valued at $9,504,000 after buying an additional 362 shares in the last quarter. Private Client Services LLC acquired a new position in Eli Lilly and Company in the 4th quarter valued at $543,000. Keel Point LLC grew its holdings in Eli Lilly and Company by 2.4% in the 4th quarter. Keel Point LLC now owns 2,060 shares of the company’s stock valued at $1,201,000 after buying an additional 49 shares in the last quarter. Aurora Private Wealth Inc. grew its holdings in Eli Lilly and Company by 26.5% in the 4th quarter. Aurora Private Wealth Inc. now owns 1,130 shares of the company’s stock valued at $659,000 after buying an additional 237 shares in the last quarter. Finally, Sippican Capital Advisors grew its holdings in Eli Lilly and Company by 21.9% in the 4th quarter. Sippican Capital Advisors now owns 4,677 shares of the company’s stock valued at $2,726,000 after buying an additional 841 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Down 0.7 %

Eli Lilly and Company stock traded down $5.56 during trading on Tuesday, hitting $745.21. 738,610 shares of the company were exchanged, compared to its average volume of 3,059,090. The business’s 50 day moving average is $762.68 and its 200 day moving average is $655.54. Eli Lilly and Company has a 52 week low of $367.35 and a 52 week high of $800.78. The company has a market capitalization of $708.07 billion, a P/E ratio of 128.77, a PEG ratio of 1.65 and a beta of 0.34. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The business had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. During the same quarter in the prior year, the company posted $2.09 earnings per share. Eli Lilly and Company’s revenue was up 28.1% compared to the same quarter last year. Analysts predict that Eli Lilly and Company will post 12.46 earnings per share for the current year.

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of the company’s stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the completion of the sale, the insider now owns 99,333,810 shares in the company, valued at $64,375,262,246.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.13% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Barclays increased their target price on Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research report on Wednesday, February 7th. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. DZ Bank cut Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 target price for the company. in a research note on Wednesday, February 21st. BMO Capital Markets raised their target price on Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 7th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $815.00 target price on shares of Eli Lilly and Company in a research note on Monday. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus target price of $728.05.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.